PACE-CME.org was present at ACC Scientific Sessions 2017 in Washington, DC. Follow the latest CV news here.
PCSK9 Expert Opinions Prof. Wolfgang Koenig describes the results of FOURIER and SPIRE. PCSK9 inhibitors will be drugs of great value in the future, especially for patients with FH and statin intolerance.
ACC 2017 A substudy of ARISTOTLE showed that new users of digoxin had a four-fold risk of sudden death, and higher plasma digoxin levels were associated with higher risk, also in AF patients who used digoxin at baseline.
PCSK9 Expert Opinions Prof. Richard Hobbs states that recent data from FOURIER show that effective medical treatment to lower LDL-c reduces endpoints that are important and expensive both for individuals and for health systems.
ACC 2017 Matthias Götberg summarises the advantages of the registry-based trial design of the randomised IFR-SWEDEHEART trial and shares the results of this study into clinical outcomes after IFR as compared with FFR.
ACC 2017 Dr. Philip Wells presented the EINSTEIN-CHOICE study, in which two doses rivaroxaban were shown to be more effective than aspirin in the prevention of recurrent VTE in the long run.
ACC 2017 Dr. Rob Nolan presented the results of the REACH study, in which multi-medial e-counselling significantly improved antihypertensive therapy adherence, and it lowered blood pressure.
PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.
ACC 2017 Dr. P.J. Devereaux presented the VISION study, in which hs-TNT turned out to be an independent predictor of CV events and mortality around non-cardiac surgery. A post-operative peak value was determined that indicates increased risk.
PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.
PCSK9 Expert Opinions Dr. Paul M. Ridker states that from FOURIER and SPIRE it becomes clear that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.
PCSK9 Expert Opinions Prof. Kausik Ray describes the practical implications of the PCSK9 outcome trials. In terms of efficacy, there is no J-shaped curve, meaning there is no apparent diminution of benefit to very low LDL
PCSK9 Expert Opinions Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy. He puts the data into perspective of other trials and molecules.